Clinicopathologic Features of Submucosal Papillary Gastric Cancer Differ from Those of Other Differentiated-Type Histologies.


Journal

Gut and liver
ISSN: 2005-1212
Titre abrégé: Gut Liver
Pays: Korea (South)
ID NLM: 101316452

Informations de publication

Date de publication:
15 01 2021
Historique:
received: 02 10 2019
revised: 19 01 2020
accepted: 21 01 2020
pubmed: 17 4 2020
medline: 18 9 2021
entrez: 17 4 2020
Statut: ppublish

Résumé

Papillary gastric cancer (GC) is classified as differentiated adenocarcinoma, together with well-differentiated (WD) and moderately differentiated (MD) adenocarcinoma. This study evaluated the risk of lymph node metastasis (LNM) in submucosal (SM) invasive papillary GC compared with other differentiated early GC types. This retrospective study involved three tertiary hospitals and enrolled 1,798 lesions with differentiated SM invasive GC treated with curative gastrectomy between March 2001 and December 2012. All pathology slides were reviewed, and clinicopathologic findings associated with LNM, including tumor size, location, gross type, ulceration, depth and width of SM invasion, and lymphovascular invasion (LVI), were analyzed. The proportion of SM papillary GC was 2.8% (n=51). SM papillary GC was associated with larger tumor size and deeper and wider SM invasion than other differentiated GC types. LNM was significantly higher in the papillary type than in the MD and WD types. LNM was found in 27.5% of SM papillary GC patients (WD: 9.0%, MD: 21.2%). LVI was the only significant risk factor for LNM in SM papillary GC. The depth or width of SM invasion was not associated with LNM in papillary GC. Lower third location or elevated gross appearance was significantly associated with LVI. SM papillary GC had the highest LNM rate, with features different from those of other differentiated SM invasive GCs. The treatment strategy for SM papillary GC should be carefully approached, especially for lesions located in the lower third or of the elevated gross type.

Sections du résumé

Background/Aims
Papillary gastric cancer (GC) is classified as differentiated adenocarcinoma, together with well-differentiated (WD) and moderately differentiated (MD) adenocarcinoma. This study evaluated the risk of lymph node metastasis (LNM) in submucosal (SM) invasive papillary GC compared with other differentiated early GC types.
Methods
This retrospective study involved three tertiary hospitals and enrolled 1,798 lesions with differentiated SM invasive GC treated with curative gastrectomy between March 2001 and December 2012. All pathology slides were reviewed, and clinicopathologic findings associated with LNM, including tumor size, location, gross type, ulceration, depth and width of SM invasion, and lymphovascular invasion (LVI), were analyzed.
Results
The proportion of SM papillary GC was 2.8% (n=51). SM papillary GC was associated with larger tumor size and deeper and wider SM invasion than other differentiated GC types. LNM was significantly higher in the papillary type than in the MD and WD types. LNM was found in 27.5% of SM papillary GC patients (WD: 9.0%, MD: 21.2%). LVI was the only significant risk factor for LNM in SM papillary GC. The depth or width of SM invasion was not associated with LNM in papillary GC. Lower third location or elevated gross appearance was significantly associated with LVI.
Conclusions
SM papillary GC had the highest LNM rate, with features different from those of other differentiated SM invasive GCs. The treatment strategy for SM papillary GC should be carefully approached, especially for lesions located in the lower third or of the elevated gross type.

Identifiants

pubmed: 32295332
pii: gnl19328
doi: 10.5009/gnl19328
pmc: PMC7817937
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-52

Commentaires et corrections

Type : CommentIn

Références

Gastric Cancer. 2017 Nov;20(6):978-986
pubmed: 28271420
J Gastroenterol. 2015 Apr;50(4):424-34
pubmed: 25142800
Gastroenterology. 1987 Sep;93(3):506-14
pubmed: 3301516
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
Surg Endosc. 2018 Apr;32(4):2114-2122
pubmed: 29067581
Gastrointest Endosc. 2010 Sep;72(3):508-15
pubmed: 20554277
Cancer Metastasis Rev. 2003 Dec;22(4):375-84
pubmed: 12884912
Cancer. 2000 Aug 15;89(4):724-32
pubmed: 10951333
Ann Surg. 1989 Nov;210(5):596-602
pubmed: 2818028
Ann Surg Oncol. 2012 Mar;19(3):779-85
pubmed: 21964889
World J Gastroenterol. 2015 Apr 7;21(13):3944-52
pubmed: 25852280
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Gastric Cancer. 2018 Jul;21(4):680-688
pubmed: 29280035
Ann Surg Oncol. 2015;22(6):1806-12
pubmed: 25605510
Clin Cancer Res. 2000 Sep;6(9):3581-4
pubmed: 10999748
Gastroenterology. 1972 Oct;63(4):584-92
pubmed: 5077145
Br J Surg. 2004 Apr;91(4):457-9
pubmed: 15048747
Gastric Cancer. 2000 Aug 4;3(1):33-38
pubmed: 11984707
Surgery. 2003 Oct;134(4):720-7; discussion 727-9
pubmed: 14605635
Ann Surg. 2007 Nov;246(5):749-53
pubmed: 17968165
J Cancer. 2017 Jan 1;8(1):117-123
pubmed: 28123605
Digestion. 2009;80(3):173-81
pubmed: 19776581
Endoscopy. 1998 Aug;30(6):548-52
pubmed: 9746164
Surg Endosc. 2013 Mar;27(3):1000-8
pubmed: 23052530
Gut Liver. 2015 Nov 23;9(6):720-6
pubmed: 25473081
Endoscopy. 2005 Jun;37(6):570-8
pubmed: 15933932
Dig Endosc. 2011 Jan;23(1):30-6
pubmed: 21198914
J Gastroenterol. 2013 Jun;48(6):706-12
pubmed: 23090003
Dig Surg. 2002;19(5):333-9
pubmed: 12435900
Surg Endosc. 2015 Jun;29(6):1476-83
pubmed: 25249150
Cancer. 1993 Dec 1;72(11):3174-8
pubmed: 8242540
J Surg Oncol. 2006 Sep 15;94(4):275-80; discussion 274
pubmed: 16917863
Blood. 2004 Nov 15;104(10):3228-30
pubmed: 15271802
J Gastroenterol. 2003;38(1):37-44
pubmed: 12560920
Gastric Cancer. 2000 Dec;3(4):219-225
pubmed: 11984739
J Gastrointest Oncol. 2012 Sep;3(3):251-61
pubmed: 22943016
Scand J Gastroenterol. 2010 Dec;45(12):1480-7
pubmed: 20645676
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S772-7
pubmed: 26242372
Ann Surg. 2009 Nov;250(5):791-7
pubmed: 19809298
Gastric Cancer. 2019 Mar;22(2):363-368
pubmed: 30039320
Hum Pathol. 2013 Dec;44(12):2829-36
pubmed: 24139210
Surgery. 2000 Sep;128(3):408-16
pubmed: 10965312
Br J Surg. 2009 Oct;96(10):1157-61
pubmed: 19705373

Auteurs

Seung Yong Shin (SY)

Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

Jie-Hyun Kim (JH)

Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Myeong-Cherl Kook (MC)

Department of Pathology, Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Do Youn Park (DY)

Department of Pathology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
St. Maria Pathology Laboratory, Busan, Korea.

Keun Won Ryu (KW)

Department of Surgery, Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Il Ju Choi (IJ)

Department of Internal Medicine, Center for Gastric Cancer, National Cancer Center, Goyang, Korea.

Sung Hoon Noh (SH)

Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Hyunki Kim (H)

Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Yong Chan Lee (YC)

Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH